Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has earned a consensus rating of “Moderate Buy” from the twelve research firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $19.1111.

A number of research firms recently weighed in on FULC. Bank of America raised their price target on Fulcrum Therapeutics from $6.00 to $7.00 and gave the company an “underperform” rating in a report on Tuesday, December 9th. Wall Street Zen cut Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. JPMorgan Chase & Co. assumed coverage on Fulcrum Therapeutics in a research note on Monday, January 12th. They issued an “overweight” rating and a $20.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Wednesday, October 8th. Finally, Citigroup reissued an “underperform” rating on shares of Fulcrum Therapeutics in a report on Monday, December 8th.

Fulcrum Therapeutics Stock Down 2.3%

Shares of Fulcrum Therapeutics stock opened at $10.14 on Monday. Fulcrum Therapeutics has a 12-month low of $2.32 and a 12-month high of $15.74. The stock has a market capitalization of $548.78 million, a P/E ratio of -8.59 and a beta of 3.20. The company has a 50-day simple moving average of $10.89 and a 200 day simple moving average of $8.88.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Wednesday, October 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02). On average, equities analysts anticipate that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

Insider Buying and Selling at Fulcrum Therapeutics

In related news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of Fulcrum Therapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the sale, the insider directly owned 6,053,960 shares in the company, valued at $84,634,360.80. This trade represents a 40.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $11.87, for a total value of $178,050.00. Following the sale, the director directly owned 469,864 shares of the company’s stock, valued at $5,577,285.68. This represents a 3.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 4,205,139 shares of company stock valued at $58,711,943 over the last three months. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several institutional investors have recently modified their holdings of FULC. Aberdeen Group plc lifted its holdings in Fulcrum Therapeutics by 809.0% in the fourth quarter. Aberdeen Group plc now owns 1,254,027 shares of the company’s stock valued at $14,183,000 after buying an additional 1,116,066 shares during the period. SG Americas Securities LLC bought a new stake in shares of Fulcrum Therapeutics during the 4th quarter valued at $133,000. PharVision Advisers LLC bought a new stake in shares of Fulcrum Therapeutics during the 3rd quarter valued at $220,000. Quarry LP acquired a new position in shares of Fulcrum Therapeutics in the 3rd quarter valued at $35,000. Finally, Nantahala Capital Management LLC boosted its position in shares of Fulcrum Therapeutics by 8.9% in the 3rd quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock worth $42,971,000 after purchasing an additional 382,485 shares during the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.